Biomarkers in mood disorders research: Developing new and improved therapeutics

Mark J. Niciu, Daniel C. Mathews, Dawn F. Ionescu, Erica Richards, Maura L. Furey, Peixiong Yuan, Allison C. Nugent, Ioline D. Henter, Rodrigo Machado-Vieira, Carlos A. Zarate

Research output: Contribution to journalArticle

Abstract

Background: Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective: The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods: These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results: To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion: These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalRevista de Psiquiatria Clinica
Volume41
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Mood Disorders
Biomarkers
Ketamine
Research
Psychiatry
Treatment-Resistant Depressive Disorder
Metabolomics
Neurobiology
Major Depressive Disorder
N-Methylaspartate
Therapeutics
Bipolar Disorder
Neuroimaging
Proteomics
Antidepressive Agents
Public Health

Keywords

  • Anxiety
  • Biomarker
  • Bipolar disorder
  • Depression
  • Drug development

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Niciu, M. J., Mathews, D. C., Ionescu, D. F., Richards, E., Furey, M. L., Yuan, P., ... Zarate, C. A. (2014). Biomarkers in mood disorders research: Developing new and improved therapeutics. Revista de Psiquiatria Clinica, 41(5), 131-134. https://doi.org/10.1590/0101-60830000000027

Biomarkers in mood disorders research : Developing new and improved therapeutics. / Niciu, Mark J.; Mathews, Daniel C.; Ionescu, Dawn F.; Richards, Erica; Furey, Maura L.; Yuan, Peixiong; Nugent, Allison C.; Henter, Ioline D.; Machado-Vieira, Rodrigo; Zarate, Carlos A.

In: Revista de Psiquiatria Clinica, Vol. 41, No. 5, 01.01.2014, p. 131-134.

Research output: Contribution to journalArticle

Niciu, MJ, Mathews, DC, Ionescu, DF, Richards, E, Furey, ML, Yuan, P, Nugent, AC, Henter, ID, Machado-Vieira, R & Zarate, CA 2014, 'Biomarkers in mood disorders research: Developing new and improved therapeutics', Revista de Psiquiatria Clinica, vol. 41, no. 5, pp. 131-134. https://doi.org/10.1590/0101-60830000000027
Niciu, Mark J. ; Mathews, Daniel C. ; Ionescu, Dawn F. ; Richards, Erica ; Furey, Maura L. ; Yuan, Peixiong ; Nugent, Allison C. ; Henter, Ioline D. ; Machado-Vieira, Rodrigo ; Zarate, Carlos A. / Biomarkers in mood disorders research : Developing new and improved therapeutics. In: Revista de Psiquiatria Clinica. 2014 ; Vol. 41, No. 5. pp. 131-134.
@article{9608c79cc478419d8a486bfca74050a7,
title = "Biomarkers in mood disorders research: Developing new and improved therapeutics",
abstract = "Background: Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective: The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods: These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results: To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion: These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.",
keywords = "Anxiety, Biomarker, Bipolar disorder, Depression, Drug development",
author = "Niciu, {Mark J.} and Mathews, {Daniel C.} and Ionescu, {Dawn F.} and Erica Richards and Furey, {Maura L.} and Peixiong Yuan and Nugent, {Allison C.} and Henter, {Ioline D.} and Rodrigo Machado-Vieira and Zarate, {Carlos A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1590/0101-60830000000027",
language = "English (US)",
volume = "41",
pages = "131--134",
journal = "Revista de Psiquiatria Clinica",
issn = "0101-6083",
publisher = "Lemos Editorial e Graficos Ltda",
number = "5",

}

TY - JOUR

T1 - Biomarkers in mood disorders research

T2 - Developing new and improved therapeutics

AU - Niciu, Mark J.

AU - Mathews, Daniel C.

AU - Ionescu, Dawn F.

AU - Richards, Erica

AU - Furey, Maura L.

AU - Yuan, Peixiong

AU - Nugent, Allison C.

AU - Henter, Ioline D.

AU - Machado-Vieira, Rodrigo

AU - Zarate, Carlos A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective: The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods: These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results: To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion: These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.

AB - Background: Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective: The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods: These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results: To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion: These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.

KW - Anxiety

KW - Biomarker

KW - Bipolar disorder

KW - Depression

KW - Drug development

UR - http://www.scopus.com/inward/record.url?scp=84918808576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918808576&partnerID=8YFLogxK

U2 - 10.1590/0101-60830000000027

DO - 10.1590/0101-60830000000027

M3 - Article

AN - SCOPUS:84918808576

VL - 41

SP - 131

EP - 134

JO - Revista de Psiquiatria Clinica

JF - Revista de Psiquiatria Clinica

SN - 0101-6083

IS - 5

ER -